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7INSERM U757, University Paris Sud 11, Orsay, FranceBackground & Aims: PFIC2 is caused by mutations in ABCB11 sient neonatal cholestasis of possible immune mediated mecha-
encoding BSEP. In most cases affected children need liver trans-
plantation that is thought to be curative. We report on two
patients who developed recurrent normal GGT cholestasis mim-
icking primary BSEP disease, after liver transplantation.
Methods: PFIC2 diagnosis was made in infancy in both patients
on absence of canalicular BSEP immunodetection and on ABCB11
mutation identiﬁcation. Liver transplantation was performed at
age 9 (patient 1) and 2.8 (patient 2) years without major compli-
cations. Cholestasis with normal GGT developed 17 and 4.8 years
after liver transplantation, in patient 1 and patient 2, respectively,
during an immunosuppression reduction period.
Results: Liver biopsies showed canalicular cholestasis, giant
hepatocytes, and slight lobular ﬁbrosis, without evidence of
rejection or biliary complications. An increase in immunosup-
pression resulted in cholestasis resolution in only one patient.
Both patients developed atrial ﬁbrillation, and one melanonychia.
The newborn of patient 1 developed transient neonatal normal
GGT cholestasis. Immunoﬂuorescence staining of normal human
liver sections with patient’s sera, collected at the time of chole-
stasis, and using an anti-human IgG antibody to detect serum
antibodies, showed reactivity to a canalicular epitope, likely to
be BSEP. Indeed, Western blot analysis showed that patient 2
serum recognized rat Bsep.
Conclusions: Allo-immune mediated BSEP dysfunction may
occur after liver transplantation in PFIC2 patients leading to a
PFIC2 like phenotype. Extrahepatic features and/or offspring tran-Journal of Hepatology 20
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Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a
recessive hereditary cholestasis of childhood caused by muta-
tions in the ABCB11 gene, which encodes the canalicular bile salt
export pump (BSEP) only expressed in hepatocytes. PFIC2 is char-
acterized by infancy onset of jaundice with severe pruritus and
failure to thrive, persistently normal serum gamma-glutamyl
transpeptidase (GGT) activity, elevated serum bile acids, lobular
cholestasis with a diffuse giant cell transformation of hepato-
cytes, absence of canalicular BSEP staining, and profound reduc-
tion of biliary secretion of bile salts [1–4]. Progression of liver
injury towards end-stage liver disease, lack of an effective medi-
cal treatment, and increased risk of hepatic malignancy make
liver transplantation necessary for patients affected by the severe
form, usually before adolescence [1–3].
So far, liver transplantation (LT) has been considered as cura-
tive for patients with PFIC2 [2,5]. Recently, four pediatric
patients, successfully transplanted for PFIC2 were reported to
develop cholestasis recurrence with the histological and bio-
chemical features of primary BSEP deﬁciency [6,7]. Patients had
no immunodetectable BSEP in their native livers. Anti-BSEP anti-
bodies causing impairment of biliary bile acid secretion were
identiﬁed in their post-LT sera. Among 20 children transplanted
for PFIC2 at the pediatric liver centre of Bicêtre Hospital, two
developed episodes of normal GGT cholestasis with features
resembling primary BSEP deﬁciency [2, E. Jacquemin, personal
data]. Here we describe their clinical, biochemical, and histolog-
ical evolution after LT. We provide evidence that these two chil-
dren who had no immunodetectable BSEP in their native livers,10 vol. 53 j 981–986
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likely did not develop tolerance to this protein and have devel-
oped an antibody mediated immune response to donor BSEP.Patients
Patient 1: This girl presented in 1981, at four months of age, with
hepatocellular cholestasis, persistently normal serum GGT activ-
ity and numerous giant hepatocytes. Intractable pruritus, cirrho-
sis, and growth failure required a deceased donor LT that was
performed at age nine. Diagnosis of PFIC2 was based on negative
canalicular BSEP staining on liver tissue, very low concentration
of primary bile acids in bile, and identiﬁcation of biallelic ABCB11
mutations (Table 1). Immune suppression was induced with
prednisone and cyclosporine. No major problems were recorded
following LT. Serum liver tests and liver ultrasonography was
normal. At 13.5 years old, while undergoing decreased immune
suppression, she developed subicterus and pruritus. Serum liver
tests were abnormal except for GGT activity (Table 2). Increasing
doses of prednisone (0.5 mg/kg/day) and cyclosporine (blood
through levels of 200–250 ng/ml) led to disappearance of pruri-
tus and jaundice and to normalization of serum liver tests within
2 months. This episode of normal GGT cholestasis remained
unexplained. At age 24 years, she gave birth to a normal male
newborn. During a second pregnancy at age 26 years, immune
suppression was reduced. At 6th month of pregnancy she pre-
sented with normal GGT cholestasis, severe pruritus and jaun-
dice (Table 2). Liver ultrasonography was normal. She was
treated with ursodeoxycholic acid (600 mg/day) and cholestyr-
amine (16 g/day) without any improvement and she underwent
a premature delivery giving birth to a hypotrophic female new-
born. After delivery, a liver biopsy was performed and showed
lobular cholestasis with diffuse giant cell transformation ofTable 1. Characteristics at liver transplantation of the two patients wit
Patient
Gender
Patient 1
Female
ABCB11
mutations
Compound
heterozygous
c.301delCA
p.Q101DfsX8
      and
c.2944G>A
p.G982R
     with
c.1331T>C
p.V444A
Negative
0.1 mmol/L
9 years
SC
P
Growth failure
Cirrhosis
Hepatocellu
cholestasis
Giant 
hepatocyte
Portal 
inflammatio
Patient 2
Male
Homozygous 
c.77-19T>A
leading to 
abnormal 
splicing*:
p.Y26Ifs7X
Homozygous
c.1331T>C
p.V444A
Negative
NA
2.8 years
SC
P
Growth failure
Cirrhosis
Hepatocellu
cholestasis
Giant 
hepatocyte
Canalicular BSEP 
staining
Age at LT
Indication
Native liver
histology
Biliary bile acids
(N >10 mmol/L)
SC, severe cholestasis; P, pruritus refractory to medical management; PT, prothrombin tim
transpeptidase; BSEP, bile salt export pump, LT, liver transplantation; NA, not available
982 Journal of Hepatology 201hepatocytes and absence of signs of rejection or of biliary
obstruction. Cyclosporine and prednisone doses were increased
for 8 months, but cholestasis did not improve. In the meantime
her baby developed intrahepatic-cholestasis characterized by
normal GGT serum activity, that spontaneously disappeared
within 4 months. The patient was listed for a second LT. Intrave-
nous immunoglobulins produced a transitory reduction of total
serum bilirubin and bile acids (Table 3). Moreover, she devel-
oped melanonychia of hands and feet (Fig. 1). An atrial ﬁbrilla-
tion was documented after a malaise and she died due to
cardiac arrest 6 h after admission to the hospital (Table 3). Some
pre-transplant data concerning patient 1 have been reported
elsewhere (PFIC2 No. 25, [2]).
Patient 2: Born from consanguineous parents, this boy devel-
oped hepatocellular cholestasis at age 1 month, characterized
by persistent serum normal GGT activity and by numerous giant
hepatocytes. Unremitting pruritus, cirrhosis, and severe growth
failure developed. PFIC2 diagnosis was based on negative BSEP
canalicular immunostaining and identiﬁcation of biallelic ABCB11
mutations (Table 1). A deceased donor LT was performed at age
2.8 years with cyclosporine and prednisone regimen. An acute
rejection was diagnosed three weeks post-LT and it was success-
fully treated with steroid boluses. Donor liver showed a normal
canalicular BSEP staining (data not shown). An unexplained acute
episode of normal GGT cholestasis with severe pruritus, discolor-
ation of stools and subicterus, occurred 4.8 years after LT, with
decreasing immune-suppression (Table 2). Liver ultrasonography
was normal. Liver biopsy showed canalicular cholestasis and
giant hepatocytes, with slight centrilobular ﬁbrosis, and absence
of signs of rejection or of biliary obstruction. Cyclosporine and
prednisone doses were increased and azathioprine was intro-
duced. Cholestasis resolved after three months of therapy
(Table 3). Ten years post-LT, liver histology showed ﬁbrosis andh recurrent normal GGT cholestasis.
lar
s
n
36 234 N 17
lar
s
139
100
76 420 2xN 20
PT
(N >70%)
Total bilirubin
(N <17µmol/L)
ALT
(N <40 IU/L) AFP
Serum liver tests at LT
GGT
(N <60 IU/L)
e; ALT, alanine aminotransferase; AFP; alpha fetoprotein; GGT, gamma-glutamyl
; *, in silico test predicts abnormal splicing [2].
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Table 2. Clinical course of the two patients with recurrent normal GGT cholestasis after liver transplantation.
Patient
Patient 1
Circumstances and IS at 
cholestasis attack
Episode n°1$:
Decrease of IS 
Cyclosporine (blood through 
levels: 150-200 ng/ml) and 
prednisone 0.25 mg/kg every 
other day 
Episode n°2:
Decrease of IS since third 
month of pregnancy
Cyclosporine (blood through 
levels: 50-75 ng/ml) and 
prednisone 0.1 mg/kg every 
other day
Pruritus
40 months post-LT
No liver biopsy performed
Pruritus
4.8 years post-LT
Liver biopsy performed
4.8 years post-LT
Decrease of IS 
Cyclosporine (blood through 
levels: 150-200 ng/ml) and 
prednisone 0.2 mg/kg every 
other day
Pruritus
17 years post-LT during the 
6th month of a 2nd
pregnancy.
Liver biopsy performed after 
delivery
Patient 2
90
85
100
32
620
32
160
600
31
35
45 352
14
107
298
First symptom and delay to 
onset of normal GGT 
cholestasis* after LT
PT
(N >70%)
Total bilirubin
(N <17µmol/L)
Bile acids
(N <15 µmol/L)
ALT
(N <40 IU/L)
Serum liver tests during cholestatic flare
GGT
(N <60 IU/L)
IS, immunosuppression regimen; PT, prothrombin time; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; LT, liver transplantation; *, cholestasiswithout
rejection, infection, or biliary or vascular complications; NA, not available; $, Evolution of episode n1 after adaptation of IS is described in the case report of patient 1.
Table 3. Evolution after recurrence of normal GGT cholestasis* on liver graft.
Patient Adaptation of IS
Patient 1
Symptoms Last follow-up
Unremitting P
SC
Hard hepatomegaly
Hyperkeratosis of 
hands and feets
Melanonychia
Disappearance of 
pruritus without 
recurrence
Episode n°2:
Increase of cyclosporine dose 
(blood through levels:
200-250 ng/ml) and of 
prednisone 0.3 mg/kg every 
day
Intravenous immunoglobulins: 
one injection of 1 g/kg
At age 28 years:
SC with persistence of abnormal liver 
tests. Abrupt malaise. Atrial fibrillation. 
Cardiac arrest and death, while awaiting 
for a 2nd LT
Ten years post-LT:
Liver histology: no rejection but slight 
portal and lobular fibrosis with giant 
hepatocytes
Unexplained polyclonal hyper gamma-
globulinemia (18.5 g/L)
Non organ specific autoantibodies: 
negative
Alive at age 22 years with normal clinical 
exam and serum liver tests. 
Atrial fibrillation of unknown cause
Offspring:
Transient neonatal cholestasis with normal 
serum GGT and spontaneous resolution 
within 4 months
Increase of cyclosporine dose 
(blood through levels:
250-300 ng/ml) and of 
prednisone 0.5 mg/kg every 
day
Azathioprine started: 
1.2 mg/kg every day
Patient 2
93
100
513
1
150
5
PT
(N >70%)
Total bilirubin
(N <17µmol/L)
Bile acids
(N <15 µmol/L)
Serum liver tests
IS, immunosuppression regimen; PT, prothrombin time; GGT, gamma-glutamyl transferase; LT, liver transplantation; *, cholestasis without rejection, infection, or biliary or
vascular complications; SC, severe cholestasis; P, pruritus refractory to medical management.
JOURNAL OF HEPATOLOGYpersistence of numerous giant hepatocytes. Prednisone was
stopped 17 years after LT. At age 22, the patient is alive with nor-
mal growth and sexual maturation, receiving azathioprine
(0.8 mg/kg/day) and cyclosporine (1.3 mg/kg/day; blood through
levels: 25–50 ng/ml). Serum liver tests and renal function are
normal. Cholestasis did not recur. The patient developed an atrial
ﬁbrillation of unknown cause (Table 3).Journal of Hepatology 201Methods
ABCB11 sequence analysis, bile analysis
Sequence analysis was performed as described [2]. Mutation screening was done
using PCR ampliﬁcation and DNA sequencing of coding exons 2–28 and all splice
junctions of ABCB11 (RefSeq NM_003742.2). Combined in silico splice tools were0 vol. 53 j 981–986 983
Fig. 1. Melanonychia involving nails of hands and feet that developed in
patient 1 after liver transplantation.
Case Reportused to test the potential effect on pre-mRNA splicing of the homozygous intronic
variation found in patient 2 [2]. Biliary concentration of bile acids was measured
using standard procedures [2].
Liver histology and immunohistochemistry
Native and post-transplant liver samples were studied in both patients. A poly-
clonal anti-BSEP and a monoclonal anti-MDR3 (Sigma–Aldrich) antibody were
used as described on parafﬁn-embedded sections [2,3,8].
Immunoﬂuorescence analysis
Indirect immunoﬂuorescence staining was performed as described [7]. Post-
transplant serum samples from the two patients obtained during cholestatic epi-
sodes were screened at dilutions ranging from undiluted to 1:500 with the use of
normal human liver sections. For the shown experiments, patient sera were used
diluted at 1:25. Bound antibodies were detected using ﬂuorescein isothiocyanate
conjugated rabbit anti-human IgG, IgA, and IgM antibodies (dilution: 1:100, Dak-
oCytomation). Sera from two patients transplanted for biliary atresia and
obtained 10 years after LT were used similarly, and served as a control.
Western blot analysis
Rat bile salt export pump (Bsep)-GFP-transfected HEK293 cells were used for
Western blotting as previously described [2,6,8]. Serum of patient 2 (dilution:
1:50) was available and detected with a peroxidase-conjugated anti-human-984 Journal of Hepatology 201IgG-speciﬁc antibody (1:2000). Control sera were used similarly. Bsep-GFP was
detected using anti-green ﬂuorescent protein (GFP) antibody (dilution: 1:400,
Roche, France).Results
Native liver histology, native and post-LT liver
immunohistochemistry, and immunoﬂuorescence analyses
Native liver histology and immunohistochemistry studies
showed a typical PFIC2 pattern, as shown in patient 2 (Fig. 2A
and B) [2]. Post-transplant liver histology revealed a PFIC2 pat-
tern, as shown in patient 1 (Fig. 2C). Canalicular BSEP immuno-
staining performed 17.3 years post-LT, during a bout of normal
GGT cholestasis, was negative in patient 1 (Fig. 2D). In patient
2, canalicular BSEP immunostaining was faintly positive during
a bout of normal GGT cholestasis, occurring 4.8 years post-LT
(Fig. 2E). In both patients, canalicular MDR3 immunostaining
used as a control was positive. In patient 2, giant hepatocytes
were observed 10 years post-LT as well as ﬁbrosis (Fig. 2F).
Immunoﬂuorescence staining of normal human liver sections
incubated with the serum of each patient collected at the time of
the cholestasis bout, revealed, using an anti-human IgG antibody,
clear staining of bile canaliculi (Fig. 2G and H). No staining was
seen using anti-human IgA and IgM antibodies (data not shown).
When normal liver sections were incubated with control sera, no
canalicular staining was seen (Fig. 2G).
Western blot analysis
To test the hypothesis that antibodies reacting with epitopes in
bile canaliculi were directed against BSEP, a serum sample from
patient 2 was analyzed by immunoblotting using proteins from
cells expressing Bsep. The anti-GFP antibody immunoreacted
with a protein of approximately 180 kDa in Bsep-GFP-transfected
cells. Patient serum reacted with a protein of the same molecular
mass in Bsep-GFP-transfected cells but not in control GFP-trans-
fected cells, revealing Bsep as the antibody target (Fig. 3) [6,7].
Control sera did not recognize Bsep (data not shown).Discussion
PFIC2 is a common indication for pediatric LT. This procedure is
thought to cure the genetic disease and recurrent disease related
to immunization of the recipient against donor BSEP protein, but
has, until very recently, not been considered [1,2,5–7]. This study
reports the clinical course and the long term evolution of two
patients, successfully transplanted for PFIC2, and who developed
after LT, episodes of normal GGT cholestasis with features sug-
gesting recurrence of BSEP dysfunction. Thus, our report rein-
forces the idea that recurrence of BSEP dysfunction after LT,
secondary to an allo-immunization process in a patient immuno-
logically ‘‘naive” for BSEP, may represent a novel clinico-patho-
logical entity more than a rare and sporadic phenomenon. The
chronology of this condition is variable with a wide range of time
between liver transplantation and the development of cholesta-
sis. The severity spectrum ranges from mild cases that can be
reversed by increasing the immunosuppression regimen as in
patient 2 and in the patients reported by Jara et al. [7], to severe
episodes with very limited or no response to medical therapy,0 vol. 53 j 981–986
Fig. 2. Initial and/or post-transplantation liver histology in patients 1 and 2, transplanted for PFIC2 (A, B, E, F, and H: patient 2. C, D, and G: patient 1). (A) Native liver
histology (HE stain) showing numerous giant hepatocytes (star), canalicular cholestasis (arrowhead), inﬂammation and septal ﬁbrosis. (B) Negative immunohistochemical
detection of canalicular BSEP in native liver. Note positive canalicular MDR3 immunostaining (Inset). (C) Liver histology (HE stain) 17.3 years post-transplantation showing
numerous giant hepatocytes (star) and canalicular cholestasis (arrow). (D) Negative immunohistochemical detection of canalicular BSEP 17.3 years post-transplantation.
Note positive canalicular MDR3 immunostaining (Inset). (E) Faint immunohistochemical detection of canalicular BSEP 4.8 years post-transplantation. Note positive
canalicular MDR3 immunostaining (Inset). (F) Trichrome stain, and Sirius red stain (Inset) 10 years post-transplantation showing thin septal, perisinusoidal and
centrilobular ﬁbrosis and numerous giant hepatocytes (star). (G) Patient 1 serum collected 17.3 years post-transplantation was used for immunoﬂuorescent staining of
normal human liver. Antibodies within the serum sample were detected by an anti-human IgG antibody (lower part). Serum contained antibodies reactive to a canalicular
epitope. A serum collected 10 years post-transplantation from a liver patient transplanted for biliary atresia was used as control and was not reactive to canaliculus (upper
part). (H) Patient 2 serum collected 4.8 years post-transplantation was used for immunoﬂuorescent staining of normal human liver as indicated in G. Serum contained
antibodies reactive to a canalicular epitope. Original magniﬁcation: A, B, C, D, and F: 125; E and H: 250; G: 400.
100
150
250
1 2 3kDa
Fig. 3. Western blot showing reactivity of serum from patient 2 to rat bile salt
export pump (Bsep). Lanes 1 and 3: Bsep-GFP-transfected HEK293 cells; lane 2:
control GFP-transfected HEK293 cells. Protein lysates were incubated with anti-
GFP antibody (lane 1), and patient 2 serum (lanes 2 and 3). Bsep (arrow, 180 kDa)
could be detected with anti-GFP antibody (lane 1) or patient 2 serum (lane 3) in
Bsep-GFP-HEK293 transfected cells, but not in GFP-HEK293 transfected cells
(lane 2).
JOURNAL OF HEPATOLOGYrequiring liver retransplantation, as in patient 1 and in the
patient reported by Keitel et al. [6]. Allo-immune induced BSEP
dysfunction may be underdiagnosed in the post-transplant
course because of its rapid resolution by increasing the immuno-
suppression regimen.
In the four previously reported patients, presence of anti-BSEP
IgG antibody, suggested an allo-immune reaction of the recipient
directed against BSEP of the donor liver [6,7]. It is assumed that
these IgG allo-antibodies are internalized by hepatocytes, trans-
ported throughout the cell and reach the canaliculus membrane
where they exert their blocking effect on BSEP [7,9–11]. TheJournal of Hepatology 201mechanisms that lead to allo-immune reaction are not precisely
known and one can only hypothesize. Allo-immune reaction
implies a loss of tolerance by the host of the graft towards wild
type BSEP [6,7,12]. This may occur if an antigenic part of BSEP
is exposed to blood lymphocytes, under post-transplant circum-
stances such as hepatocyte necrosis due to infection or rejection,
BSEP misrouting to the basal membrane of the hepatocytes, or
regurgitation from bile to blood through increased paracellular
permeability due to biliary obstruction [6,13,14]. Whether preg-
nancy may play a role in the loss of tolerance is not known. When
performed, BSEP immunostaining showed no canalicular BSEP in
mostly all native livers of PFIC2 patients [2–4]. In some cases (i.e.
premature stop codon), BSEP is probably not expressed at all,
explaining the lack of tolerance and the development of anti-
BSEP antibodies following LT. In other instances (i.e. missense
mutation), BSEP is retained in the endoplasmic reticulum, and
peptides resulting from its degradation might be presented to
immune cells and induce tolerance [15]. This might explain
why disease recurrence after LT is not observed in all PFIC2
patients. Considering the genotypes of the 2 patients we report
on, no or little protein expression was expected in their native
livers [2,3,6,15]. Conditions favoring or triggering allo-immuniza-
tion in patients transplanted for PFIC2 are unknown, but in our
two patients as well as in two of the previously reported patients,
reduction of immunosuppression was noted [7].
In both our patients, sera collected during the cholestatic epi-
sodes were tested against normal human liver tissue by immuno-
ﬂuorescence, and revealed an IgG speciﬁc canalicular reactivity.
This suggests the presence of an antibody of IgG class speciﬁcally
reacting against an epitope in bile canaliculus of normal liver0 vol. 53 j 981–986 985
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[6,7]. Canalicular BSEP immunostaining of the transplanted liver
of each patient, using an anti-BSEP antibody, was negative or
faint. It is likely that allo-anti-BSEP IgG antibodies produced by
the patient partially or completely mask the BSEP epitope recog-
nized by anti-BSEP antibody. Western blot analysis showed
strong evidence for BSEP being the target of allo-antibodies.
Indeed, Bsep was recognized by patient serum and BSEP is highly
identical to its rat ortholog [7,8]. In addition, the clinical and bio-
chemical picture of a normal GGT cholestasis associated with fea-
tures akin to PFIC2, together with absence of histological
evidence of the most common causes of cholestasis in liver-trans-
planted patients, such as rejection or biliary complications,
strongly support an allo-immune induced BSEP dysfunction in
our patients. The presence of associated extra-hepatic phenom-
ena, not yet reported in this condition, further supports the
immune-mediated nature of this entity. Indeed, atrial-ﬁbrillation
may be caused by an immune-mediated mechanism [16], and
melanonychia is known to be associated with immune-mediated
disorders [17]. Interestingly, the baby from patient 1 developed
neonatal normal GGT cholestasis that spontaneously resolved
within 4 months. ABCB11 heterozygous status has been found
to favour transient neonatal cholestasis, characterized by slightly
elevated serum GGT activity [18]. In this baby, likely harbouring a
ABCB11mutated allele transmitted from his mother, transplacen-
tal transfer of anti-BSEP antibodies might have led to transient
blockage of the function of the wild type BSEP encoded by the
normal allele, and favored transient neonatal cholestasis with
normal serum GGT activity.
These data conﬁrm that allo-immune BSEP dysfunction may
occur after LT in PFIC2 patients with no immunodetectable BSEP
in their native livers. It may develop even many years after an
apparently well-controlled transplantation. Allo-antibodies gen-
erated against BSEP of donor liver may inhibit BSEP function
and cause cholestasis with PFIC2 like phenotype. It may be treat-
able or not by increasing immunosuppression and can lead to
graft failure requiring re-transplantation. Extrahepatic features
and/or offspring transient-neonatal normal GGT cholestasis of
possible immune mediated mechanisms, can be associated. Liver
transplanted PFIC2 patients should be carefully monitored for the
appearance of anti-BSEP antibodies. An immunosuppression reg-
imen increase before normal GGT cholestasis onset might avoid
insidious progression of ﬁbrosis in the liver graft. Prospective
strategies should be established to prevent ‘‘disease recurrence”
in high-risk patients.Conﬂict of interest
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